Portal de Periódicos da CAPES

Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models

2024; Wiley; Volume: 96; Issue: 1 Linguagem: Inglês

10.1002/jmv.29354

1096-9071

Jindřich Činátl, Marco Bechtel, Philipp Reus, Mélanie Ott, Florian Rothweiler, Martin Michaelis, Sandra Ciesek, Denisa Bojková,

Immunotherapy and Immune Responses

Abstract The Mpox virus can cause severe disease in the susceptible population with dermatologic and systemic manifestations. Furthermore, ophthalmic manifestations of mpox infection are well documented. Topical trifluridine (TFT) eye drops have been used for therapy of ophthalmic mpox infection in patients, however, its efficacy against mpox virus infection in this scenario has not been previously shown. In the present study, we have established ophthalmic cell models suitable for the infection with mpox virus. We show, that TFT is effective against a broad range of mpox isolates in conjunctival epithelial cells and keratocytes. Further, TFT remained effective against a tecovirimat‐resistant virus strain. In the context of drug combinations, a nearly additive effect was observed for TFT combinations with brincidofovir and tecovirimat in conjunctival epithelial cells, while a slight antagonism was observed for both combinations in keratocytes. Altogether, our findings demonstrate TFT as a promising drug for treatment of ophthalmic mpox infection able to overcome tecovirimat resistance. However, conflicting results regarding the effect of drug combinations with approved compounds warrant close monitoring of such use in patients.